• 1
    Kahlmeter G, Brown DFJ, Goldstein F et al. European harmonisation of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 2003; 52: 145148.
  • 2
    National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th edn. Approved Standard M7-A5. Wayne, PA: NCCLS, 2000.
  • 3
    Comité de l’Antibiogramme de la Société Française de Microbiologie. Technical recommendations for in vitro susceptibility testing. Clin Microbiol Infect 1996; 2 (suppl 1): S11S25 (updates on
  • 4
    Deutsches Institut für Normung. Medical microbiology—susceptibility testing of pathogens to antimicrobial agents. Berlin: DIN, 1999.
  • 5
    Commissie Richtlijnen Gevoeligheidsbepalingen. Interpretatie van gevoeligheidsonderzoek en gevoeligheidscriteria voor antibacteriële middelen in Nederland. Nederlands Tijdschrift Med Microbiol 2000; 3: 7981.
  • 6
    Bergan T, Bruun JN, Digranes A, Lingaas E, Melby KK, Sander J. Susceptibility testing of bacteria and fungi. Scand J Infect Dis 1997; 103 (suppl): 136.
  • 7
    The Swedish Reference Group of Antibiotics. Antimicrobial susceptibility testing in Sweden. Scand J Infect Dis Suppl 1997; 105: 531 (updates on
  • 8
    MacGowan AP, Wise R. Establishing MIC breakpoints and interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001; 48 (suppl S1): 1728 (updates on
  • 9
    The European Society for Clinical Microbiology and Infectious Diseases . URL: (last accessed 28 December 2006).
  • 10
    Wong-Beringer A, Hindler J, Loeloff M et al. Molecular correlation for the treatment outcomes in blood stream infections caused by Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2002; 34: 135146.
  • 11
    Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella penumoniae bacteremia implications of production of extended spectrum beta-lactamases. Clin Infect Dis 2004; 39: 3137.
  • 12
    Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Med 2006; 119 (suppl 1): S20S28.
  • 13
    Bhavnani SM, Ambrose PG, Craig WA et al. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006; 54: 231236.
  • 14
    Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165174.
  • 15
    Andes D, Craig WA. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 2005; 11 (suppl 6): 1017.
  • 16
    Jones RN, Craig WA, Ambrose PG et al. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing ESBLs. Diagn Microbiol Infect Dis 2005; 52: 235246.
  • 17
    Hope R, Potz NAC, Warner EJ et al. Efficacy of practised screening methods for detection of cephalosporine resistant Enterobacteriaceae. J Antimicrob Chemother 2007; 59: 110113.
  • 18
    Jacoby GA, Walsh KE, Walker V. Identification of extended-spectrum, AmpC, and carbapenem hydrolyzing beta-lactamases in Escherichia coli and Klebsiella pneumoniae by disk test. J Clin Microbiol 2006; 44: 19711976.